1 May 2011AmericasKatie Wang

Attacking the validity of selection patents

The conclusion is not surprising: a selection patent will not receive special treatment. Its validity is vulnerable to attack on any of the grounds provided in the Patent Act. Accordingly, a determination that the conditions for a select patent have not been met does not constitute an independent basis upon which to attack the validity of the patent (Eli Lilly Canada Inc. v Novopharm Limited).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 March 2026   Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.
Americas
12 March 2026   The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.
Americas
12 March 2026   The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.